TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorTargetCancer Foundation
About this trial
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
Eligibility criteria
Qualifiers
Provision of signed and dated informed consent form.
Stated willingness to comply with all study related blood draws and assessments for the duration of the study.
Individuals who are 18 years old or older at the time of consent.
Patients with a rare (fewer than 6 cases per 100,000 per year) solid tumor or lymphoma with evaluable disease at baseline. The complete list of included cancers are included in the study protocol; diseases not listed in the study protocol may be enrolled with the approval of the Principal Investigator.
Disqualifiers
Participants who are unable to provide informed consent.
Participants who are 17 years of age or younger.
Participants who are unable to comply with the study procedures.
Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.
Trial design
Treatments tested in this trial
- FoundationOne CDx and FoundationOne Liquid CDx
Treatment groups
400 Participants
are divided into 3 treatment groupsSponsors and collaborators
TargetCancer Foundation
Lead sponsor
Foundation Medicine
Collaborator
Source ClinicalTrials.gov